3,4-dihydroxyphenylacetic acid has been researched along with Encephalopathy, Toxic in 19 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| " DOPAL is well known to exhibit toxic effects on neuronal cells." | 1.62 | Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity. ( Ito, S; Ojika, M; Sugumaran, M; Tanaka, H; Wakamatsu, K, 2021) |
| " Male Sprague-Dawley (SD) rats were dosed orally with ACR at 0 (saline), 20, 30, and 40 mg/kg/day for 20 days." | 1.42 | Acrylamide increases dopamine levels by affecting dopamine transport and metabolism related genes in the striatal dopaminergic system. ( Cheng, G; Guo, X; Lu, Q; Pan, X; Xiong, F; Yan, H, 2015) |
| "5Gy) TBI, C57BL/6 mice were administered with MPTP (15mg/kg, four times, 2h apart) intraperitoneally (i." | 1.35 | Potential mechanisms of neuroprotection induced by low dose total-body gamma-irradiation in C57 mice administered with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Guo, Q; Li, S; Liang, Y; Su, B; Wen, C; Zhang, Y, 2009) |
| " Although increasing the dosage of d-METH (20 to 80 mg/kg) did increase the GFAP response (100% over control), it was still well below that usually exhibited at the usual neurotoxic dosage (300-400% over control) in fully mature mice." | 1.31 | Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure. ( Ali, SF; Miller, DB; O'Callaghan, JP, 2000) |
| " To determine if the vesicular pool of DA was essential for the expression of METH-induced DA neurotoxicity, reserpine (3 mg/kg, given iintraperitoneally 24-26 h prior to METH) was given prior to a toxic dose regimen of METH." | 1.31 | Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. ( Callahan, BT; McCann, UD; Ricaurte, GA; Yuan, J, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, S | 1 |
| Tanaka, H | 1 |
| Ojika, M | 1 |
| Wakamatsu, K | 1 |
| Sugumaran, M | 1 |
| Miner, NB | 1 |
| Elmore, JS | 1 |
| Baumann, MH | 1 |
| Phillips, TJ | 1 |
| Janowsky, A | 1 |
| Enayah, SH | 1 |
| Vanle, BC | 1 |
| Fuortes, LJ | 1 |
| Doorn, JA | 1 |
| Ludewig, G | 1 |
| Ngwa, HA | 1 |
| Kanthasamy, A | 1 |
| Jin, H | 1 |
| Anantharam, V | 1 |
| Kanthasamy, AG | 1 |
| Pan, X | 1 |
| Guo, X | 1 |
| Xiong, F | 1 |
| Cheng, G | 1 |
| Lu, Q | 1 |
| Yan, H | 1 |
| Zhang, Y | 1 |
| Li, S | 1 |
| Liang, Y | 1 |
| Wen, C | 1 |
| Guo, Q | 1 |
| Su, B | 1 |
| Dluzen, DE | 1 |
| McDermott, JL | 1 |
| Darvesh, AS | 1 |
| Ali, SF | 3 |
| Bondy, SC | 1 |
| Li, CR | 1 |
| Huang, GB | 1 |
| Sui, ZY | 1 |
| Han, EH | 1 |
| Chung, YC | 1 |
| Chen, H | 1 |
| Wu, J | 1 |
| Zhang, J | 1 |
| Fujita, Y | 1 |
| Ishima, T | 1 |
| Iyo, M | 1 |
| Hashimoto, K | 1 |
| Bradner, JM | 1 |
| Suragh, TA | 1 |
| Wilson, WW | 1 |
| Lazo, CR | 1 |
| Stout, KA | 1 |
| Kim, HM | 1 |
| Wang, MZ | 1 |
| Walker, DI | 1 |
| Pennell, KD | 1 |
| Richardson, JR | 1 |
| Miller, GW | 1 |
| Caudle, WM | 1 |
| Muramatsu, Y | 1 |
| Kurosaki, R | 1 |
| Mikami, T | 1 |
| Michimata, M | 1 |
| Matsubara, M | 1 |
| Imai, Y | 1 |
| Kato, H | 1 |
| Itoyama, Y | 1 |
| Araki, T | 1 |
| Gehrke, BJ | 1 |
| Harrod, SB | 1 |
| Cass, WA | 1 |
| Bardo, MT | 1 |
| Tanaka, K | 1 |
| Ogawa, N | 1 |
| Jiang, B | 1 |
| Zhang, H | 1 |
| Bi, J | 1 |
| Zhang, XL | 1 |
| Kita, T | 1 |
| Matsunari, Y | 1 |
| Saraya, T | 1 |
| Shimada, K | 1 |
| O'Hara, K | 1 |
| Kubo, K | 1 |
| Wagner, GC | 1 |
| Nakashima, T | 1 |
| Imam, SZ | 1 |
| Islam, F | 1 |
| Itzhak, Y | 1 |
| Slikker, W | 1 |
| Miller, DB | 1 |
| O'Callaghan, JP | 1 |
| Yuan, J | 1 |
| Callahan, BT | 1 |
| McCann, UD | 1 |
| Ricaurte, GA | 1 |
19 other studies available for 3,4-dihydroxyphenylacetic acid and Encephalopathy, Toxic
| Article | Year |
|---|---|
Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Neurotoxicity Syndromes; Oxidation-Reduction; Par | 2021 |
Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Body Temperature Regulation; Brain; Ce | 2017 |
PCB95 and PCB153 change dopamine levels and turn-over in PC12 cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Male; Neurotoxicity Syndromes; PC12 Cells; Polych | 2018 |
Vanadium exposure induces olfactory dysfunction in an animal model of metal neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Disease Models, Animal; Dopamin | 2014 |
Acrylamide increases dopamine levels by affecting dopamine transport and metabolism related genes in the striatal dopaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acrylamide; Administration, Oral; Animals; Corpus Striatum; Dopamine | 2015 |
Potential mechanisms of neuroprotection induced by low dose total-body gamma-irradiation in C57 mice administered with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chroma | 2009 |
Relationships among gender, age, time, and temperature in methamphetamine-induced striatal dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Body Temperature; Central Nervous System Stimu | 2010 |
Red wine but not ethanol at low doses can protect against the toxicity of methamphetamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Central Nervous System Depressants; Centra | 2010 |
Effects of 6-hydroxydopamine lesioning of the medial prefrontal cortex on social interactions in adolescent and adult rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Dopamine; Exploratory Behavior; Interpersonal Relati | 2010 |
Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Basal Ganglia; Behavior, Animal; Dopamine; Do | 2012 |
Exposure to the polybrominated diphenyl ether mixture DE-71 damages the nigrostriatal dopamine system: role of dopamine handling in neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cell Count; Cells, Cultured; Chromato | 2013 |
Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Arginine; Bra | 2002 |
The effect of neurotoxic doses of methamphetamine on methamphetamine-conditioned place preference in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Temperature; Body Weight; Brain Chemistry; Central Ner | 2003 |
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Dis | 2005 |
Neuroprotective activities of catalpol on MPP+/MPTP-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2008 |
Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine-Related Disorders; Animals; Behavior, Animal; Body Tempe | 2000 |
Prevention of dopaminergic neurotoxicity by targeting nitric oxide and peroxynitrite: implications for the prevention of methamphetamine-induced neurotoxic damage.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; | 2000 |
Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Area Under Curve; Body Temperature; Central Nervous | 2000 |
Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; Animals; Body Temperature; Brain Chemistry; Cy | 2001 |